\(\beta\)-Cell Hyperplasia Induced by Hepatic Insulin Resistance

DSpace/Manakin Repository

\(\beta\)-Cell Hyperplasia Induced by Hepatic Insulin Resistance

Show simple item record

dc.contributor.author Escribano, Oscar
dc.contributor.author Guillén, Carlos
dc.contributor.author Nevado, Carmen
dc.contributor.author Gómez-Hernández, Almudena
dc.contributor.author Kahn, C. Ronald
dc.contributor.author Benito, Manuel
dc.date.accessioned 2012-12-07T20:53:29Z
dc.date.issued 2009
dc.identifier.citation Escribano, Oscar, Carlos Guillén, Carmen Nevado, Almudena Gómez-Hernández, C. Ronald Kahn, and Manuel Benito. 2009. \(\beta\)-cell hyperplasia induced by hepatic insulin resistance. Diabetes 58(4): 820-828. en_US
dc.identifier.issn 0012-1797 en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:10019709
dc.description.abstract Objective: Type 2 diabetes results from a combination of insulin resistance and impaired insulin secretion. To directly address the effects of hepatic insulin resistance in adult animals, we developed an inducible liver-specific insulin receptor knockout mouse (iLIRKO). Research Design and Methods: Using this approach, we were able to induce variable insulin receptor (IR) deficiency in a tissue-specific manner (liver mosaicism). Results: iLIRKO mice presented progressive hepatic and extrahepatic insulin resistance without liver dysfunction. Initially, iLIRKO mice displayed hyperinsulinemia and increased \(\beta\)-cell mass, the extent of which was proportional to the deletion of hepatic IR. Our studies of iLIRKO suggest a cause-and-effect relationship between progressive insulin resistance and the fold increase of plasma insulin levels and \(\beta\)-cell mass. Ultimately, the \(\beta\)-cells failed to secrete sufficient insulin, leading to uncontrolled diabetes. We observed that hepatic IGF-1 expression was enhanced in iLIRKO mice, resulting in an increase of circulating IGF-1. Concurrently, the IR-A isoform was upregulated in hyperplastic \(\beta\)-cells of iLIRKO mice and IGF-1–induced proliferation was higher than in the controls. In mouse \(\beta\)-cell lines, IR-A, but not IR-B, conferred a proliferative capacity in response to insulin or IGF-1, providing a potential explanation for the \(\beta\)-cell hyperplasia induced by liver insulin resistance in iLIRKO mice. Conclusions: Our studies of iLIRKO mice suggest a liver-pancreas endocrine axis in which IGF-1 functions as a liver-derived growth factor to promote compensatory pancreatic islet hyperplasia through IR-A. en_US
dc.language.iso en_US en_US
dc.publisher American Diabetes Association en_US
dc.relation.isversionof doi://10.2337/db08-0551 en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661585/pdf/ en_US
dash.license LAA
dc.subject Metabolism en_US
dc.title \(\beta\)-Cell Hyperplasia Induced by Hepatic Insulin Resistance en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal Diabetes en_US
dash.depositing.author Kahn, C. Ronald
dc.date.available 2012-12-07T20:53:29Z
dash.affiliation.other HMS^Medicine-Brigham and Women's Hospital en_US

Files in this item

Files Size Format View
2661585.pdf 1.147Mb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters